| abstract |
The present invention relates to the use of a CDK2 and / or CDK7 and / or CDK9 inhibitor, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating a disease associated with antinuclear antibodies, wherein the CDK2 inhibitor and / or CDK7 and / or CDK9 or a pharmaceutically acceptable salt thereof is administered in an amount sufficient for the reductive regulation of antinuclear antibody levels. A further aspect of the invention relates to a combination comprising a CDK2 and / or CDK7 and / or CDK9 inhibitor, or a pharmaceutically acceptable salt thereof, and methylprednisolone, and its use in the treatment of diseases associated with antinuclear antibodies, just like SLE. |